Milestone
6.3.a
Technology landscape
Completed
Ongoing
Create and maintain a comprehensive landscape of universal influenza vaccine technologies in preclinical and clinical development and develop a mechanism to update and analyze the landscape, including identifying key factors underlying successful R&D efforts as well as persistent challenges and obstacles.
Progress Highlights
CIDRAP at the University of Minnesota, with funding from the Global Funders Consortium for Universal Influenza Vaccine Development, developed and maintains the Universal Influenza Vaccine Technology Landscape, which is updated regularly.
Taaffe 2024 reviewed the next-generation influenza vaccine pipeline, focusing on products in clinical development, and compared their characteristics to currently approved seasonal influenza vaccines.